Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

CDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two independent pathways contributing to multiple I&I; diseasesCDX-622 targets the soluble form of stem cell factor (SCF), depleting mast cells without measurably impacting other KIT functionsRapid, profound,...